Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 538Neoplasms 393Prostatic Neoplasms 261Colorectal Neoplasms 252Lung Neoplasms 202Carcinoma, Hepatocellular 177Stomach Neoplasms 162Pancreatic Neoplasms 151Rectal Neoplasms 143Motor Activity 128Colonic Neoplasms 126Carcinoma, Non-Small-Cell Lung 118Uterine Cervical Neoplasms 113Polycystic Ovary Syndrome 96Head and Neck Neoplasms 96Esophageal Neoplasms 92Neoplasm Metastasis 71Brain Neoplasms 68Liver Neoplasms 67Ovarian Neoplasms 65Recurrence 60Urinary Bladder Neoplasms 59Pain 55Fatigue 54Lymphoma 53Endometrial Neoplasms 52Anxiety Disorders 50Melanoma 48Thyroid Neoplasms 47Pain, Postoperative 41

Interventions

pyrotinib 1Vinorelbine 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Unknown × HER2 Positive Breast Cancer × Clear all
NCT03947242 2019-05-15

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.

Henan Cancer Hospital

Phase NA Unknown
48 enrolled
Breast

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡